VBI Vaccines
22 Third Street, Suite 2241
Cambridge
Massachusetts
02142
United States
Tel: 617-830-3031
Website: http://www.vbivaccines.com/
Email: info@vbivaccines.com
180 articles about VBI Vaccines
-
VBI Vaccines Announces Proposed Public Offering of Common Shares
9/18/2019
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI or the Company), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that it has commenced an underwritten public offering of its common shares.
-
Clinical Catch-Up: September 9-13
9/16/2019
Last week was a busy one for clinical trial results, particularly with the European Committee for Treatment and Research in Multiple Sclerosis 2019 Congress going on. Here’s a look at some of the top clinical trial stories. -
VBI Vaccines Announces Phase 2a Clinical Evaluation of VBI-1901 Cancer Vaccine Candidate in Combination with GSK’s AS01B Adjuvant System in Recurrent Glioblastoma Patients
9/10/2019
VBI Vaccines Inc. announced a collaboration with GlaxoSmithKline (GSK) to clinically evaluate the combination of VBI-1901, VBI’s cancer vaccine immunotherapeutic, with GSK’s proprietary AS01B adjuvant system.
-
Clinical Catch-Up for June 17-21
6/24/2019
Plenty of biopharma companies released results from clinical trials last week. Here’s a look at the top stories. -
Here’s a look at some of last week’s clinical trial announcements, including some from the American Society of Clinical Oncology Annual Meeting you might have missed.
-
VBI Vaccines Appoints Christopher McNulty as Chief Financial Officer and Head of Business Development
8/15/2018
VBI Vaccines Inc.
-
VBI Vaccines to Participate in the 2018 Oppenheimer Boston Oncology Insight Summit
7/9/2018
VBI Vaccines Inc. today announced that the company will participate in the Oppenheimer Boston Oncology Insight Summit July 10 – 11, 2018.
-
VBI Vaccines to Present at 2018 JMP Securities Life Sciences Conference
6/19/2018
VBI Vaccines Inc. announced that Jeff Baxter, President and CEO, will present at the JMP Securities Life Sciences Conference
-
VBI Vaccines Announces Changes to its Board of Directors
1/29/2018
The Pontifax Group, with the nomination of Tomer Kariv, Chairman and Chief Executive Officer of The Pontifax Group, to replace Ran Nussbaum, managing partner and co-founder of The Pontifax Group.
-
VBI Vaccines Announces Dosing of First GBM Patient in Phase I/IIa Clinical Study of VBI-1901
1/17/2018
The multi-center, open-label, two-part study will enroll up to 28 patients and is designed to evaluate safety, tolerability, and the optimal therapeutic dose level of VBI-1901.
-
VBI Vaccines Announces Initiation of Phase III Clinical Program for Sci-B-Vac Hepatitis B Vaccine
12/19/2017
VBI announced today the initiation of the global Phase 3 clinical program for Sci-B-Vac, its third-generation hepatitis B vaccine, with the commencement of patient dosing on December 18, 2017.
-
VBI Vaccines Strengthens Board of Directors With Appointment of Ran Nussbaum
11/2/2017
“We are honored to have Ran join our Board of Directors,” said Jeff Baxter, VBI’s president and CEO.
-
VBI Vaccines Announces Closing of Public Offering and Concurrent Registered Direct Offering of Common Shares
10/31/2017
VBI also closed its concurrent registered direct offering of 7,475,410 common shares at a price of US$3.05 per share.
-
VBI Vaccines Announces Full Exercise of Underwriters' Option to Purchase Additional Shares and Upsized Registered Direct Offering for Aggregate Proceeds of $71.9M
10/30/2017
The pricing for the underwritten public offering was for a total of 16,100,000 common shares.
-
VBI Vaccines Prices Concurrent Public Offering and Registered Direct Offering for Aggregate Proceeds of $63.5M
10/26/2017
The pricing for the underwritten public offering was for a total number of 14,000,000 common shares for expected gross proceeds of US$42.7 million
-
VBI Vaccines Announces Proposed Concurrent Public Offering and Registered Direct Offering of Common Shares
10/26/2017
VBI also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of common shares offered in the public offering.
-
VBI Vaccines Booming in Kendall Square, Ottawa and Israel
10/9/2017
-
VBI Vaccines Reports Positive Outcome From Phase III Pre-IND Discussions With The FDA For Hepatitis B Vaccine, Sci-B-Vac
6/19/2017
-
Meet VBI Vaccines, The Biotech Up 100% In 2017
3/8/2017
-
VBI Vaccines Receives Positive Response From Health Canada’s Initial Evaluation Of The Proposed Sci-B-Vac Phase III Clinical Program
2/22/2017